Outset Medical (NASDAQ:OM) EVP Marc Nash Sells 5,375 Shares

Outset Medical, Inc. (NASDAQ:OM) EVP Marc Nash sold 5,375 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $27,520.00. Following the sale, the executive vice president owned 42,785 shares in the company, valued at $219,059.20. The trade was a 11.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Marc Nash also recently made the following trade(s):

• On Wednesday, January 21st, Marc Nash sold 980 shares of Outset Medical stock. The shares were sold at an average price of $4.98, for a total value of $4,880.40.
• On Wednesday, January 7th, Marc Nash sold 108 shares of Outset Medical stock. The stock was sold at an average price of $4.27, for a total value of $461.16.
• On Monday, November 17th, Marc Nash sold 247 shares of Outset Medical stock. The stock was sold at an average price of $4.60, for a total value of $1,136.20.

Outset Medical Stock Performance

Shares of OM opened at $5.20 on Thursday. Outset Medical, Inc. has a 1 year low of $3.10 and a 1 year high of $21.98. The company has a market cap of $94.38 million, a price-to-earnings ratio of -0.40 and a beta of 2.07. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.77 and a current ratio of 7.09. The firm has a fifty day moving average of $4.33 and a 200-day moving average of $11.03.

Outset Medical News Roundup

Here are the key news stories impacting Outset Medical this week:

• Negative Sentiment: CEO Leslie Trigg sold a total of 13,914 shares across Jan. 20–21 (two filings), reducing her stake; the bulk was sold at ~ $5.12 per share. These disclosures can be viewed on the SEC filing. CEO Filings
• Negative Sentiment: General Counsel John L. Brottem sold a total of 10,494 shares across Jan. 20–21 at ~ $5.01–$5.12 per share, cutting his position materially (one filing shows a ~20% reduction). See the SEC disclosure. GC Filings
• Negative Sentiment: EVP Marc Nash sold 6,355 shares across Jan. 20–21 at ~ $4.98–$5.12 per share, reducing his holding by double-digit percentages in one filing. See the SEC filing for details. EVP Filings

Institutional Investors Weigh In On Outset Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new position in Outset Medical during the 2nd quarter valued at $34,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Outset Medical in the second quarter valued at $35,000. BNP Paribas Financial Markets boosted its stake in Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after buying an additional 2,034 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in Outset Medical during the second quarter worth about $78,000. Finally, New York State Common Retirement Fund acquired a new position in Outset Medical during the second quarter worth about $108,000.

Wall Street Analysts Forecast Growth

Several research analysts have commented on OM shares. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Stifel Nicolaus reduced their price objective on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 7th. Wall Street Zen cut Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $7.00 target price on shares of Outset Medical in a research note on Wednesday, December 17th. Finally, BTIG Research reiterated a “buy” rating and set a $17.00 price target on shares of Outset Medical in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.67.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.